The Three-Stream Problem
An antibody-drug conjugate is not one product. It is three manufacturing streams converged into one: monoclonal antibody production, cytotoxic payload synthesis, and bioconjugation.
The VP CMC for an ADC programme must have genuine fluency across all three. This immediately eliminates most conventional CMC leaders, who typically come from either a biologics background or a small molecule background but rarely both.
Containment Expertise Is Non-Negotiable
ADC payloads are among the most toxic compounds handled in pharmaceutical manufacturing. Occupational exposure levels are measured in nanograms. The VP CMC must understand OEB-5 and OEB-6 containment requirements not as an abstract concept but as an operational reality that shapes facility design, equipment selection, cleaning validation strategy, and personnel safety protocols.
Candidates who have only worked with standard potency compounds will face a steep and risky learning curve.
Where the Candidates Are
The qualified talent pool sits primarily in three places: the established ADC companies (Seagen legacy within Pfizer, Daiichi Sankyo, AbbVie/ImmunoGen), the specialist ADC CDMOs (Lonza, Abzena, Novasep), and a small number of biotech companies with advanced ADC programmes.
Experienced leaders remain scarce relative to demand. Expect significant competition for candidates with commercial-stage ADC CMC experience.
Compensation Premium
VP CMC roles in ADC carry a 15-25% compensation premium over comparable roles in standard biologics. US base salaries range from $270,000 to $360,000 with total compensation of $370,000 to $520,000. The premium reflects both scarcity and risk.